NEKTAR THERAPEUTICS — Director's Dealing 2021

Sep 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-09-22

Reporting Person: CHESS ROBERT (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-22	Common Stock	A	10200	$0.00	Acquired	284473	Direct
2021-09-22	Common Stock	S	4600	$17.94	Disposed	279873	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-22	Stock Option	$17.78	A	20400	Acquired	2029-09-21	Common Stock (20400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2100	Indirect
Common Stock	2100	Indirect
Common Stock	2100	Indirect

Footnotes

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 22, 2021.

F3: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: This transaction was executed in multiple trades at prices ranging from $17.59 to $18.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issues.

F5: The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F6: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.